Oxford BioTherapeutics (OBT), a clinical-stage oncology firm, has announced a long-term partnership with Roche ...

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...

Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTCL The combination of ...

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

The chikungunya virus virus-like particle vaccine is well tolerated and shows high immunogenicity in both previous recipients ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

Viruses like the one that causes COVID-19 constantly mutate, rendering many antibody treatments ineffective. A Stanford-led ...

CoV-2 nucleocapsid antibodies to detect exposure to SARS-CoV-2: results from a prospective cohort study on COVID-19 ...

Researchers at King's College London have developed IgE antibodies targeting HER2-expressing cancers. Early studies show ...

Oxford Biotherapeutics Ltd. is partnering with Roche AG to expand the current field of tumor antigens that can be drugged with antibodies, as part of a potential $1 billion-plus agreement. The ...

A new type of antibody which stimulates the immune system to target cancer cells slows tumour growth, according to new research.